公开(公告)号：US20220033462A1

公开(公告)日：2022-02-03

申请号：US17385805

申请日：2021-07-26

Applicant: ALLOGENE THERAPEUTICS, INC. ,  CELLECTIS

Inventor： ARVIND RAJPAL ,  Shobha Chowdary Potluri ,  Laurent Poirot ,  Alexandre Juillerat ,  Thomas Charles Pertel ,  Donna Marie Stone ,  Barbra Johnson Sasu

IPC: C07K14/705 ,  C07K16/30 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.

公开(公告)号：US11014989B2

公开(公告)日：2021-05-25

申请号：US15546633

申请日：2016-01-25

Applicant: Cellectis

Inventor： Julianne Smith ,  Julien Valton ,  Alexandre Juillerat ,  Philippe Duchateau ,  Barbra Johnson Sasu ,  Arvind Rajpal

IPC: A61K35/17 ,  C07K16/28 ,  C07K14/725 ,  C07K16/30 ,  C12N5/00 ,  C12N5/0783 ,  A61K39/00 ,  A61K39/395 ,  C07K14/705 ,  C07K14/735 ,  G01N15/10 ,  G01N15/14 ,  G01N15/00

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward CLL1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for immunotherapy for treating cancer, in particular leukemia.

公开(公告)号：US11072644B2

公开(公告)日：2021-07-27

申请号：US15525906

申请日：2015-11-09

Applicant: ALLOGENE THERAPEUTICS, INC. ,  CELLECTIS

Inventor： Arvind Rajpal ,  Shobha Chowdary Potluri ,  Laurent Poirot ,  Alexandre Juillerat ,  Thomas Charles Pertel ,  Donna Marie Stone ,  Barbra Johnson Sasu

IPC: C07K14/705 ,  C07K16/30 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  A61K39/00

Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.